GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (STU:17Q1) » Definitions » Retained Earnings

Pharmaron Beijing Co (STU:17Q1) Retained Earnings : €845 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pharmaron Beijing Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Pharmaron Beijing Co's retained earnings for the quarter that ended in Dec. 2024 was €845 Mil.

Pharmaron Beijing Co's quarterly retained earnings increased from Jun. 2024 (€764 Mil) to Sep. 2024 (€799 Mil) and increased from Sep. 2024 (€799 Mil) to Dec. 2024 (€845 Mil).

Pharmaron Beijing Co's annual retained earnings increased from Dec. 2022 (€562 Mil) to Dec. 2023 (€668 Mil) and increased from Dec. 2023 (€668 Mil) to Dec. 2024 (€845 Mil).


Pharmaron Beijing Co Retained Earnings Historical Data

The historical data trend for Pharmaron Beijing Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Retained Earnings Chart

Pharmaron Beijing Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 242.48 447.66 562.25 668.40 845.08

Pharmaron Beijing Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 668.40 694.34 763.71 798.67 845.08

Pharmaron Beijing Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Pharmaron Beijing Co  (STU:17Q1) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Pharmaron Beijing Co Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.

Pharmaron Beijing Co Headlines

No Headlines